has part
is_specified_input_of
is_manufactured_by
has role
immunizes host
Homo sapiens
Menactra
Kallan Roan, Oliver He
WEB: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
CVX: 114
vaccine
Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
125089
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf
Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
Trade Name: Menactra
Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Menactra
USA licensed vaccine role
Canada licensed vaccine role
intramuscular vaccination
polysaccharide of pathogen organism as vaccine component
USA licensed vaccine
vaccine conjugate protein
meningococcal conjugate vaccine
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Sanofi Pasteur, Inc